PUBLICATIONS

Full manuscripts are available at my ResearchGate page

Patents

 

  1. Bartfeld E and Lass A. Apparatus and method for obtaining an identification of drugs for enhanced safety. Patent Number 9031853. Issued May 12, 2015

 

  1. Bartfeld E and Lass A. System and Method for real time management of a drug regimen. Patent number: 7747454 issued June 29, 2010

 

Book chapters

 

Amir Lass (1999, 2004) Investigation of the infertile couple for assisted conception in Brinsden, P.R. (eds) A Textbook of In Vitro fertilization and Assisted Reproduction. Parthenon Publishing, Carnforth, UK. 2nd and 3rd  editions.

 

MBA thesis

 

Amir Lass (2000) Recommendations for marketing strategy to the assisted conception unit (ACU) at Bourn Hall Clinic. University of Westminster, London. Supervisor C. Blackman

 

MA thesis

 

Amir Lass (2008) Civil-Military relations in Israel and its effect on the Second Lebanon War. University College London (UCL) Supervisor N. Locherey

 

 

 

Published Manuscripts

 

  1. Lass A. (2020) Fertility and Pregnancy in patients with familial adenomatous polyposis (FAP). European Gynecology and Obstetrics. 2020; 2(2):73-76

 

  1. LassA, Chaudary W, Lass G. (2019) Correlation between gross domestic product, utilization of in vitro fertilization, and pregnancy success rate across the world. J Med Econ. Apr 23:1-5

 

  1. Lass A. & Montgomery M (2019): RE: A cost-effectiveness modeling evaluation comparing a biosimilar follitropin alfa preparation with its reference product for live birth outcome in Germany, Italy and Spain. J Med Econ. 2019 Jan 29:1-2

 

  1. Lass A, Belluzzi A. (2018) Omega 3 polyunsaturated fatty acids (PUFA) and in vitro fertilization (IVF) treatment. Reprod Biomed Online. Jan;38(1):95-99

 

  1. Newson LR, Lass A. Effectiveness of transdermal oestradiol and natural micronised progesterone for menopausal symptoms. Br J Gen Pract. 2018 Oct;68(675):499-500.

 

  1. Lass A and Newson RL. Omega 3 polyunsaturated fatty acids and the menopause. (2018) Post Reproductive Health 24 (3) 130-1.

 

  1. Andersen V, Banerji V, Hall G, Lass A, Emmanuel AV. (2018) The patient burden of opioid-induced constipation: new insights from a large, multinational survey in 5 European countries. United European Gastroenterol J. Oct;6(8):1254-1266

 

  1. Child T, Leonard S, Evans J, Lass A. (2018) Systematic review of the clinical efficacy of vaginal progesterone for luteal phase support in assisted reproductive technology. Reprod Biomed Online 36(6):630-645.

 

  1. Lass A. (2018) Is single ovary a detrimental factor for live-birth rate in IVF? Hum Reprod. Feb 1. doi: 10.1093/humrep/dey007

 

  1. Lass A. (2017) Pharmaceutical industry contribution to research is essential but full transparency and guidelines are required, ,Hum Reprod. 32(10):2147-2148

 

  1. Lass A. (2015) Improving theReporting of Clinical Trials of Infertility Treatments (IMPRINT): modifying the CONSORT statement- what about registration studies? Hum Reprod. 30(2):490

 

  1. Hovatta O, McVeigh E, Lass A, Homburg R (2009). A large Northern European observational study of follitropin alfa filled-by-mass pre-filled pen. RBMOnline Vol 18. No 4. 502-508

 

  1. Durnerin CI, Erb K, Fleming R, Hillier H, Hillier SG, Howles CM, Hugues JN, Lass A, Lyall H, Rasmussen P, Thong J, Traynor I, Westergaard L, Yates R Luveris Pretreatment Group. (2008)   Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation. Hum Reprod;23(2):421-6

 

  1. Lass A and McVeigh E. (2004) The routine use of r-hFSH Follitropin- alfa (GONAL-f) filled-by-mass for follicular development for IVF: a large multicentre observational study in the UK. Biomed. Online. 9: 604-610.

 

  1. Lass A. (2004) Assessment of ovarian reserve – is there a role for ovarian biopsy? Debate continued. Hum. Reprod. 19; 467-9

 

  1. Lass A. (2004)  Recombinant FSH in alternative doses or versus urinary gonadotrophins for ovulation induction in subfertility associated with polycystic ovary syndrome. Hum. Reprod. 19: 217-218.

 

  1. Lass A. Vassiliev MA. Decosterd G. Warne D. Loumaye E.  (2002) The relationship of baseline ovarian volume to ovarian response in ovulation induction treatment in WHO II anovulatory patients using chronic low dose gonadotropin stimulation. Fertil Steril 78: 265-269.

 

  1. Lass A. Weiser W. Munafo A. Loumaye E. (2001) The role of Leukemia inhibitory factor (LIF) in human reproduction. Fertil Steril 76:1091-6

 

  1. Lass A, Akagbosu F. and Brinsden P. (2001) Sperm banking and ART treatment for couples following cancer treatment of the male partner. Hum. Reprod.Update. 7, 370-377.

 

  1. Lass (2001) Smoking and follicle numbers. Fertil Steril 75;1245-6.

 

  1. Lass A. (2001) Assessment of ovarian reserve – is there a role for ovarian biopsy? Hum. Reprod. 16;1055-1057.

 

  1. Lass A., and Brinsden P. (2001) How do patients choose a private IVF treatment?- a customer survey in a tertiary fertility center in the UK. Fertil. Steril. 75, 893-897.

 

  1. Abusheikha N, Lass A, Brinsden P. (2001) XX males without SRY gene and with infertility.  Hum Reprod. 16, 717-8.

 

  1. Abusheikha N., Lass A., Akagbosu F. and Brinsden P. (2001) In vitro fertilization cycles converted to intrauterine insemination because of poor follicular response have low success rate. Fertil. Steril. 75;634-635.

 

  1. Lass A. on behalf of the UK timing of hCG group (2003). Monitoring of IVF-ET cycles by ultrasound versus ultrasound and hormonal levels: a prospective, multicentre, randomized study. Fertil Steril 78: 265-269.

 

  1. Lass A., Gerrard A,  Abusheikha N, Akagbosu F. and Brinsden P. (2000) IVF performance of women who have fluctuating early follicular FSH levels. Assist. Reprod. Genet. 17; 566-573.

 

  1. Lass , Burnley A. and Brinsden P. (2000) Sperm cryopreservation for cancer patients. Fertil. Steril., 72, 418.

 

  1. Lass A, (1999) The fertility potential of women with a single ovary. Reprod. Update., 5, 546-550.

 

  1. Croucher C and Lass A, (1999) Predictive value of the results of a first IVF cycle. Hum Reprod., 14, 2417-2418.

 

  1. Lass A, Abusheika N. and Brinsden P. (1999) The effect of difficult embryo transfer on in vitro fertilisation (IVF) outcome. Reprod., 14, 2417.

 

  1. Lass A., Williams G., Abusheika N. and Brinsden P. (1999) The effect of endometrial polyps on outcomes of in vitro fertilization (IVF) cycles. Assist. Reprod. Genet., 16, 410-415.

 

  1. Lass A, (1999) What is the preferred treatment for hydrosalpinges? The ovary’s perspective. Reprod.,14, 1674-1677.

 

  1. Lass A, and Brinsden P. (1999) The role of ovarian volume in reproductive medicine. Reprod. Update, 5,256-266.

 

  1. Abusheikha N., Lass A., Akagbosu F. and Brinsden P. (1999) How useful is cervical dilatation in patients with cervical stenosis in an in vitro fertilization-embryo transfer programme? The Bourn Hall experience. Steril. 72, 610-612.

 

  1. Nahum R. Bzezinsky A., Lass A and Toth T. (1999) Age, Follicle-Stimulating Hormone, or Estradiol-Which is a better predictor of ovarian response in in vitro fertilization.  Assissted Reproduction 9, 176-179.

 

  1. Abusheikha N, Akagbosu F, Marcus S, Lass A, Cousins C, Brinsden P. (1999) Viral screening and assisted conception treatment- the Bourn Hall experience. J Assist Reprod Genet., 16, 337-339.

 

  1. Lass A, Abusheika N., Akagbosu F. and Brinsden P. (1999) Cancer patients should be offered semen cryopreservation BMJ 318, 1556.

 

  1. Lass A, Akagbosu F., Abusheikha N., Hassouneh M. Blayney M. Avery S. and Brinsden P. (1998) A program of semen cryopreservation for patients with malignant disease: Lessons from eight years experience. Hum Reprod, 11, 3256-3261.

 

  1. Lass A, Peat D., Avery S. and Brinsden P. (1998) Histological evaluation of  endometrium on the day of oocyte retrieval after GnRH-a/ FSH superovulation for IVF Hum Reprod, 11, 3203-3205.

 

  1. Abusheika N, Akagbosu F, Marcus S, Lass A, Cousins C and Brinsden P. (1998) Screening infertile couples for HIV infection. Steril., 70, 785.

 

  1. Lass A, Ellenbogen A, Croucher C, Trew G, Margara R, Becattini C and Winston RML (1998) The effect of salpingectomy on ovarian response to superovulation in an in-vitro fertilization embryo transfer programme. Fertil Steril, 70, 1035-1038.

 

  1. Lass A, Croucher C, Duffy S, Dawson K, Margara R and Winston R. (1998) 1000 initiated cycles of in vitro fertilization in women of 40 years old or more. Fertil Steril, 70, 1030-1034.

 

  1. Lass A, and Croucher C. (1998) Side of ovulationin in spontaneous cycles and during stimulation for In Vitro Fertilisation (IVF). Hum Reprod, 13, 244

 

  1. Croucher C, Lass A, Margara R and Winston R. (1998) Predictive value of the results of a first in vitro fertilization cycle on the outcome of subsequent cycles. Hum Reprod, 13, 403-408.

 

  1. Ben-Yair E, Lass A, Lev S, Ben-Yehoshua L, Tartakovsky B. (1997) Tumour necrosis factor alpha binding to human and mouse trophoblast. Cytokine 9, 830-836.

 

  1. Lass A, Croucher C, Margara R and Winston R. (1997) Right or left ovary, Which one is better? Hum Reprod, 12, 1730-1731.

 

  1. Lass A, Silye R, Abrams D.C, Krausz T, Margara R and Winston R.M.L (1997) Follicular density in ovarian biopsy of infertile woman: A novel method to assess ovarian reserve. Hum Reprod., 12, 1028-1031.

 

  1. Lass A, Paul M, Margara R and Winston RML. (1997) Women with one ovary have decreased response to GnRHa/HMG ovulation induction protocol in IVF programme but the same pregnancy rate as women with two ovaries. Hum Reprod., 12, 298-300

 

  1. Lass A, Skull J, McVeigh E, Margara R, Winston R. (1997) Measurement of ovarian volume by transvaginal sonography prior to Human Menopausal Gonadotrophin hyperstimulation can predict poor response of infertile patients in an IVF programme., Hum Reprod,., 12, 294-297.

 

  1. Ben-Yair E, Lass A, Lev S, Ben-Yehoshua L, Tartakovsky B (1997). Tumour necrosis factor alpha binding to human and mouse trophoblast. Cytokine. Nov;9(11):830-6.

 

  1. Lass A., Silye R, Abrams D.C, Krausz T, Margara R and Winston R.M.L (1996) Follicular density in ovarian biopsy of infertile woman: A novel method to assess ovarian reserve. J. Br. Fertil. Soc.

 

  1. Sinclair C.G, Lass A, Skull J, Delhanty J.D.A and Rodeck C. (1996) The role of chromosomal mosaicism in women with multiple miscarriage and IVF failure. J. Hum. Genet. 59: 2110.

 

  1. Hovatta O, Silye R, Kraus T, Abir R, Margara R, Trew G, Lass A, Winston R.M.L (1996) Cryopreservation of human ovarian tissue by using dimethyl-sulphoxide and propanediol-sucrose as cryoprotetants. Reprod.11:1268-1272.

 

  1. Ben Nun I, Lass A, Kaneti H, Ghetler Y, Shilon M, Shulman A, Bahary C, Beyth Y, Siegal A.(1992) Lack of correlation between hormonal blood levels and endometrial maturation in agonadal women with repeat implantation failure following embryo transfer from donated eggs: Assist Reprod Genet 9:102-105.

 

  1. Lass A, Goldberger S.; Bernheim B.; Ben nun I.; Fejgin M (1990) Vagina prostaglandin E2 and Fatal amniotic fluid embolus. JAMA 263 (24):3259-3260.

 

 

Conference Presentations

 

  1. Lass A and Newson RL (2019) Gender gap in editorial management and boards of top-ranking Obstetrics and Gynaecology journals. European Society of Gynecology 16-19 October, Vienna, Austria

 

  1. BanerjiV, Hall G, Chaudary W, Lass A. (2019) Contraceptive survey across 7 countries in Europe and South and Central America. European Society of Gynecology 16-19 October, Vienna, Austria

 

  1. Kaplan S, Bertoia M, Lass A, Wang F, Seeger J(2019) A longitudinal cohort study assessing the safety of extended levonorgestrel-containing combined oral contraceptive use. European Society of Gynecology 16-19 October, Vienna, Austria

 

  1. Lass A and Newson RL. (2018) Omega 3 polyunsaturated fatty acids and the menopause. British Menopause Society 28th Annual Conference, 5-6 July, Royal College of Physicians, London, UK

 

  1. Newson L, Mair R, Lass (2018) Diagnosis and management of the menopause – a survey of primary care practitioners in the UK. 16th world congress on menopause. 6-9, June Vancouver Canada

 

  1. Newson L and Lass (2018) Hormonal replacement therapy for the menopause – are all products the same? 16th world congress on menopause. 6-9, June Vancouver Canada

 

  1. Lass A (2018). Industry support to academia.  Medical Affairs Leaders Forum, , 28- February- 1st March, London UK.

 

  1. Andersen V, Lass A, Banerji V, Hall G, Emmanuel AV. (2017) Users of Weak Opioids Have a Smaller Spectrum of Constipation Symptoms, But a Similar Degree of Bother From Constipation, as Users of Potent Opioids. 25th UEG WEEK 28 October- 1 November, Barcelona, Spain

 

  1. Emmanuel AV, Banerji V, Hall G, Lass A, Andersen V. (2017) Do the new Rome IV diagnostic criteria for opioid‐induced constipation identify patients with a greater biopsychosocial burden? 25th UEG WEEK 28 October- 1 November, Barcelona, Spain.

 

  1. Andersen V, Banerji V, Hall G, Lass A, Emmanuel AV. (2017) Healthcare Professionals Fail to Provide Adequate Counselling and Support About Opioid‐induced Constipation to Strong‐Opioid Users  25th UEG WEEK 28 October- 1 November, Barcelona, Spain

 

  1. Child T, Leonard S, Evans J, Lass A. (2017) Systematic review of the clinical efficacy of vaginal progesterone for luteal phase support in assisted reproductive technology cycles.33rd annual meeting, ESHRE Geneva, Switzerland, from 2 -5 July.

 

  1. Lass A (2015). Managing the European medical affairs department. Medical Affairs Leaders Forum, Berlin Germany, 26-27 February.

 

  1. Lass A (2014). Headstones’ Text in Israeli Military Cemeteries –The conflict Between National Uniformity and Private Commemoration. British Association Jewish Studies (BAJS) Annual Conference, Dublin, Ireland; 13-15 July.

 

  1. Lass A (2013). Managing late phase studies. Late phase leaders forum, Brussels, Belgium, November 12t-14th.

 

  1. Lass A (2013). Industry support to independent research, legal code and ethical aspects. BCGIP(COGI) Congress Opening Session, Istanbul, Turkey, 30 May.

 

  1. Anstey AV, Edwards G, Lass A (2010) Severe psoriasis has a greater negative effect on quality of life than previously appreciated; a UK web-based patient survey. 90thAnnual Meeting of the British Association of Dermatologists Manchester , p-41

 

  1. Sharief, D. Dive, M. Vrethem, M. Reunanen, E. Sanders, A. Lass (2005). High-dose interferon beta-1a therapy for relapsing-remitting multiple sclerosis following dose escalation from lower dose therapy. A multi-centre observational study in Northern Europe. 21st Congress of the European Committee for the Treatment and Research in Multiple Sclerosis
    10th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis 28.September . – 01 October.

 

  1. Lass A, Lapatto R, Clayton P, Faisal A (2005). A randomised dose comparison of the effect of recombinant human growth hormone on IGF, bone and Metabolism biomarkers in prepubertal GH deficient children. ESPE/LWPES 7th Joint Meeting Pediatric Endocrinology, Lyon, France, 22nd

 

  1. Hovatta O, McVeigh E, Homburg R, Bogle S, Lass A. The Routine Use of Follitropin Alfa (FbM) Pre-filled Pen for Follicular Development for IVF. A Large Multinational Observational Study in Northern Europe. P-420 61st Annual meeting of the American Society for Reproductive Medicine (ASRM, Montreal, Canada October 2005).

 

  1. Clayton Ahmed F, Lapatto R; Lass A (2005). A randomised dose comparison of the effect of recombinant human growth hormone on IGF, bone and metabolism biomarkers in prepubertal GH deficient children. The Endocrine Society’s 87th Annual Meeting, San Diego, USA, 5th June.

 

  1. Mcveigh E and Lass A (2004). The routine use of r-hFSH Follitropin- alfa (GONAL-f) filled-by-mass for follicular development for IVF: a large multicentre observational study in the UK. 60th Annual meeting of the American Society for Reproductive Medicine (ASRM, Philadelphia, USA October.

 

  1. Lass A. (2003). The use of LH to stimulate the ovary. Serono Symposia “Reproductive Ageing” Palma de Majorca, Spain, 15 September.

 

  1. Lass A (2002). Recombinant LH. The annual meeting of Israeli Ferility Society. Tel Aviv, 24th

 

  1. McVeigh E, Auray J, Lass A and Beresniak A (2002). Pharmacoeconomic modelling of Gonal-F versus Clomiphene Citrate in ovulation induction & intrauterine insemination for women with normal ovulation. 58th Annual meeting of the American Society for Reproductive Medicine (ASRM) Seattle, USA, 12-17 October. Fertility and Sterility, 78:1001 : S85

 

  1. Lass A (2002). New developments in follicular stimulation. The Finnish Fertility Society Annual Meeting, Helsinki. Finland, 4th September

 

  1. Lass A.(2002). New advances in reproductive medicine. The Dutch Fertility Symposia. Amsterdam, April

 

  1. Wikland M.; Borg K.; Decosterd; Saunders H.; Bergstrom E.; Lass A. (2002). A new formulation of Gonal-F® filled by mass is significantly better tolerated than Puregon® liquid in patients undergoing ovarian stimulation for ART. 12th World Congress on IVF, Buenos Aires, Argentina, 12-16 March.

 

  1. Lass, A. Blackman , Bellars G., Walmsley M., and Brinsden P. (2000) How do patients choose an IVF clinic? ESHRE Bolognia,25- 28 June, R-137.

 

  1. Brinsden P, Abdalla S., Barlow D.H., Goswamy R.; Maislisch L.; Larroque S.; Engrand P.; Loumaye E and Lass A. (2001) A prospective, multicentre, randomised, patient-blind, parallel group study comparing ultrasound only criterion for administration of u-hCG with an E2/follicle ratio criterion in down-regulated patients treated with r-hFSH prior to IVF-ET. ESHRE Lusan,1-4 July.

 

  1. Lass A, Vasilliev A, Warne D and Loumaye E. (2001) The predictive value of baseline ovarian volume in PCO / WHO II anovulatory patients having ovulation induction treatment. ESHRE Lusan,1-4 July.

 

  1. Abusheikha , Lass A., Burnley A., Akagbosu F. and Brinsden P. (1999) Women who respond poorly to ovarian stimulation for IVF have disappointing success when converted to intrauterine insemination. ESHRE Bolognia,25- 28 June, O-016.

 

  1. Lass, A. Gerrard and Brinsden P. (1999) IVF treatment in women with ‘normal’ day 2 FSH levels (<12miu/ml) who had previously high basal FSH levels. Annual meeting of the American Society for Reproductive Medicine/CFAS September 25-30, p-167, S142.

 

 

  1. Lass A., Akagbosu , Abusheikha N., Burnley A., Robbins M. and Brinsden P. (1999) Correlation between sperm quality of patient suffering from cancer and the aetiology of their malignancy. Annual meeting of the American Society for Reproductive Medicine/CFAS September 25-30, p-267, S175.
  2. Lass A., Gerrard ; Avery S. and Brinsden P. (1999). Evaluation of the performance of women with fluctuating day 2 FSH levels in IVF treatment cycles. Abstract O-049, Proceedings of the 11th World Congress on IVF-ET, Sydney, Australia, 9-14 May.

 

  1. Lass A., Williams G., Abusheika , Avery S. and Brinsden P. (1998). The management of endometrial polyps in in vitro fertilization cycles. ESHRE, Goteborg,21- 24 June.

 

  1. Lass A., Akagbosu , Abusheikha N., Hassouneh M.; Blayney M.; Avery S. and Brinsden P. (1998) A program of semen cryopreservation for patients with malignant disease: Lessons from eight years experience. ESHRE, Goteborg,21- 24 June.

 

  1. Lass A., Ellenbogen , Trew G., Margara R., Becattini C. and Winston R.M. (1998). The effect of  salpingectomy  on ovarian response to superovulation in an in-vitro fertilization and embryo transfer programme. ESHRE, Goteborg,21- 24 June.

 

  1. Lass A., Peat D., Avery S. and Brinsden P. (1998). Histological evaluation of  endometrium on the day of oocyte retrieval after GnRH-a/ FSH superovulation for IVF, ESHRE, Goteborg,21- 24 June.

 

  1. Lass A. (1996) Assessment of the ageing ovary. Institute of Obstetrics and Gynaecology, Royal Postgraduate Medical School, Scientific symposium, 17 June.

 

  1. Lass A, Rosen D, Nachum R, Markov S, Kaneti H, Beyth Y, Fejgin M. (1994). Variable decelerations during pre-induction oxytocin challenge test predict fetal distress during labour in pregnancies with uncomplicated oligohydramnios. 1st World Congress of Labour and Delivery, Jerusalem, Israel, July 5.

 

  1. Lass A, Shulman A, Rashef T, Ben-Nun I, Ghetler Y, Mekory Y, Beyth Y. (1993): Assessment of the intrafollicular immunologic system in infertile patients with endometriosis. The Annual Meeting of the Israeli Society of Infertility. Tel-Aviv, Israel, April 21-22.

 

  1. Lass A, Ben Nun I, Kaneti H, Ghetler Y, Shilon M, Shulman A, Bahary C, Beyth Y, Siegal A. (1992): Lack of correlation between hormonal blood levels and endometrial maturation in agonadal women with repeat implantation failure following embryo transfer from donated eggs:The Annual Meeting of the Israeli Society of Infertility. Tel-Aviv, Israel, March 18-20.

 

  1. Lass A, Rosen D, Fejgin M, Zeitune M (1991): Fetal femur length as a predictor for Down syndrome? The Annual Meeting of Israeli Society for Medical Genetics. Jerusalem,  Israel, November 7.

 

  1. Ben-Nun I, Lass A, Ghetler Y, Jaffe R, Siegal A, Gruber A, Kaneti H, Fejgin M (1989): Progesterone supplementation initiated prior to ovulation induction accelerates the endometrial maturation and significantly improves the implantation rate after IVF-ET. 6th World Congress In-vitro Fertilization and Alternate Assisted Reproduction, Jerusalem, Israel, April 2-7.

 

  1. Laufer N, Lass A, Lewin A, Rabinowitz R, Margalioth E, Shenker JG. (1987) A multivariate analysis for the prediction of conceptions following IVF-ET. Proceedings of the 5th World Congress on IVF-ET, Norfolk, Virginia, USA.